Barclays Maintains Overweight on RXO, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Brandon Oglenski maintains an Overweight rating on RXO (NYSE:RXO) and raises the price target from $24 to $30.
July 16, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Brandon Oglenski has maintained an Overweight rating on RXO and increased the price target from $24 to $30, indicating a positive outlook for the stock.
The increase in the price target from $24 to $30 by a reputable analyst at Barclays suggests a strong positive outlook for RXO. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100